Background/Aims: To assess auxological and safety data for growth hormone (GH)-Treated children with SHOX deficiency. Methods: Data were examined for GH-Treated SHOX-deficient children (n = 521) from the observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS). For patients with near-Adult height information, GeNeSIS results (n = 90) were compared with a clinical trial (n = 28) of SHOX-deficient patients. Near-Adult height was expressed as standard deviation score (SDS) for chronological age, potentially increasing the observed effect of treatment. Results: Most SHOX-deficient patients in GeNeSIS had diagnoses of Leri-Weill syndrome (n = 292) or non-syndromic short stature (n = 228). For GeNeSIS patients with near-Adult height data, mean age at GH treatment start was 11.0 years, treatment duration 4.4 years, and height SDS gain 0.83 (95% confidence interval 0.49-1.17). Respective ages, GH treatment durations and height SDS gains for GeNeSIS patients prepubertal at baseline (n = 42) were 9.2 years, 6.0 years and 1.19 (0.76-1.62), and for the clinical trial cohort they were 9.2 years, 6.0 years and 1.25 (0.92-1.58). No new GH-related safety concerns were identified. Conclusion: Patients with SHOX deficiency who had started GH treatment before puberty in routine clinical practice had a similar height gain to that of patients in the clinical trial on which approval for the indication was based, with no new safety concerns.

Additional Metadata
Keywords Growth, Growth hormone treatment, Near-Adult height, Safety, Short stature, SHOX deficiency
Persistent URL dx.doi.org/10.1159/000452973, hdl.handle.net/1765/108342
Journal Hormone Research in Paediatrics
Citation
Benabbad, I. (Imane), Rosilio, M, Child, C.J, Carel, J.C, Ross, J.L, Deal, C.L, … Blum, W.F. (2017). Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial. Hormone Research in Paediatrics, 87(1), 42–50. doi:10.1159/000452973